Peptomyc S.L.

https://www.peptomyc.com

Peptomyc has adopted a different strategy to attack cancer cells, based on the inhibition of the oncoprotein Myc, which is found deregulated in the majority of human cancers. Although Myc plays a central role in cancer there is currently no Myc inhibitor in the market. Peptomyc designed a new generation of anti-Myc inhibitors based on a molecule called Omomyc and the goal is to develop these into clinically viable therapeutics for the treatment of cancer patients. Early testing will be directed towards glioblastoma, a disease that responds poorly to standard therapy and that has a dire prognosis. Dr. Soucek’s group has previously validated Myc inhibition by Omomyc as a therapeutic strategy against glioblastoma in preclinical mouse models. Peptomyc was founded in December 2014 by Dr. Laura Soucek, Dr. Marie-Eve Beaulieu, VHIO and ICREA, with the mission to develop a new generation of cell penetrating peptides targeting the Myc oncoprotein for cancer treatment. *

	Start	2014-12-01 established
	Industry	peptide-based drug
	Industry 2	cancer drug

	Region	Barcelona
	Country	Spain (España)
	Street	9 Av. Republica Argentina P. 2, Pta. 1
	City	08023 Barcelona
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2023-07-10

Picture Berlin Partner Top News Healthtech Company Mika 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]